Featured Press Releases

Aptamer Sciences Inc.Innovative Liver Cancer Treatment AST-201

Aptamer Sciences Inc.Innovative Liver Cancer Treatment AST-201

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

  • 15 Apr 2024

Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs...

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

Hanmi Pharmaceutical Launches

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

The Ohio State University and TAE Life Sciences have formed a landmark collaboration to advance boron drug innovation for precision cancer therapy.

The Ohio State University and TAE Life Sciences have formed a landmark collaboration to advance boron drug innovation for precision cancer therapy.

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

  • Gilead Sciences, Inc.
  • 07 Nov 2025
PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

  • PRM Pharma, LLC
  • 07 Nov 2025
Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

  • Leukogene Therapeutics Inc.
  • 05 Nov 2025
LIfT BioSciences will present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer

LIfT BioSciences will present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer

  • LIfT BioSciences
  • 05 Nov 2025
Data on BIMZELX® (bimekizumab-bkzx) in Hidradenitis Suppurativa Showed Sustained Improvements in Pain and Draining Tunnel Resolution for Three Years

Data on BIMZELX® (bimekizumab-bkzx) in Hidradenitis Suppurativa Showed Sustained Improvements in Pain and Draining Tunnel Resolution for Three Years

  • UCB
  • 03 Nov 2025
Phase 2 Data of GC Biopharma

Phase 2 Data of GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity, Published in 'Vaccine

  • GC Biopharma
  • 03 Nov 2025

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.